Veru Inc is trading at $3.73 (-11.82%) as the stock undergoes a sharp pullback following a significant rally in the previous session.
- The recent surge was driven by news of a clinical trial supply agreement with Novo Nordisk for a Phase 2b study of enobosarm.
- Investors appear to be taking profits amid broader market weakness, with major indices also trading sharply lower.
- The downward move represents a technical correction from the outsized gains triggered by the company's partnership in the weight-loss drug space.